

Solid-Phase Synthesis of N-Substituted Pyrrolidinone-Tethered N-Substituted Piperidines via Ugi Reaction

Zhang Liu and Adel Nefzi*

Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port Saint Lucie, Florida 34987

Received March 30, 2010

Starting with resin-bound glutamic acid, an efficient synthesis of N-substituted pyrrolidinones is described, using the Ugi four-component reaction (U-4CR). The same methodology is employed to produce N-substituted pyrrolidinone tethered N-substituted piperidines.

Solid-phase organic synthesis (SPOS) has emerged as a powerful approach for the rapid generation of structurally diverse compounds in the drug discovery community. One major focus of this field is the synthesis of bioactive compounds and their derivatives on the solid phase.¹ Multicomponent reactions (MCRs) are one of the best tools in modern organic synthesis because of their productivity, simple procedures, convergence, and facile execution.² One of the most important MCRs is the Ugi four-component reaction (U-4CR), in which a carboxylic acid, an amine, a carbonyl compound, and an isocyanide react in a one-step reaction, affording related compounds with variable structures.³ The Ugi four-component reaction is a powerful way to make library scaffolds containing a high number of substitution diversities. Therefore, it has been utilized very efficiently in conjugation with solid-phase organic synthesis to prepare large collections of molecules in a short reaction sequence.⁴

The N-substituted pyrrolidinone is an attractive drug template because of its extensive biological activities in various drug targets, such as aspartic protease,⁵ β -amyloid cleaving enzyme (BACE),⁶ progesterone receptor (PR),⁷ human melanocortin-4 receptor,⁸ factor Xa,⁹ and HIV-1 integrase.¹⁰ The development of new synthetic protocols for N-substituted pyrrolidinone derivatives are topics of continuous interest.¹¹ Herein, we would like to present our approach toward the solid-phase synthesis of enantiopure N-substituted pyrrolidinones, utilizing glutamic acid as a bifunctional reagent in an Ugi four-center three-component reaction (U-4C-3CR).¹² We also used the same methodology to create diversified N-substituted pyrrolidinone tethered N-substituted piperidines.

Polymer supported glutamic acid **2** was readily prepared by the coupling of L-Fmoc-Glu(^tBu)-OH to MBHA resin (Scheme 1). The generated resin bound bifunctional compound **2** was optimized for the solid phase Ugi reaction conditions. The initial attempt was carried out with benzyl isocyanide (1.1 equiv) and cyclohexanone (1.1 equiv) in acetonitrile/methanol (1:1) for 24 h at 65 °C. Following cleavage of the solid support, the desired product was

obtained in 58% yield (Table 1, entry **4a**), with traces of starting material. To drive the reaction to completion, we used varying stoichiometries of the isocyanide and ketone. The better results were obtained using 2-fold excess of the reagents with a yield of 83% (Table 1, entry **4c**). We also tested the reaction under different reaction conditions by reducing the reaction time (Table 1, entry **4d**) or by lowering the temperature (Table 1, entry **4e**). In both cases, the reaction was incomplete and lower yields were obtained.

Under the optimized conditions (Table 1, entry **4c**), the scope of the solid phase Ugi reaction was explored using various isocyanides and ketones (Table 2). Polymer-supported glutamic acid was allowed to react with different isocyanides (2 equiv) and ketones (2 equiv) to afford the corresponding products in very good yields. We tried the same reaction conditions starting from resin-bound aspartic acid. The reaction was not successful and very low yields were obtained.


To increase the diversity, we used Boc-piperidone as the carbonyl reagent for the solid-phase Ugi reaction. Following the Ugi condensation of the resin-bound free glutamic acid **2** with isocyanide and Boc-piperidone, the Boc group was deprotected with 55% TFA/DCM and the resin-bound pyrrolidinone tethered piperidine **6** was treated with diversified capping agents, such as sulfonyl chlorides, isocyanates, isothiocyanates, and carboxylic acids (Scheme 2). In all cases, the reaction proceeded smoothly and the desired products **8** were obtained in high yields (Table 3).

In conclusion, we employed polymer supported glutamic acid as an efficient bifunctional component in Ugi reaction. Using this approach, we performed the parallel solid phase synthesis of enantiopure N-substituted pyrrolidinone derivatives tethered to different biologically relevant heterocycles such as piperidine.

Experimental Section

Procedure for the Synthesis of Polymer Supported Glutamic Acid 2. A 100 mg sample of *p*-methylbenzhydrylamine hydrochloride salt (MBHA) resin (1.15 mequiv/g, 100–200 mesh) was contained within a sealed polypropylene mesh packet.¹³ Reactions were carried out in polyethylene bottles. Following neutralization of the resin

*To whom correspondence should be addressed. E-mail: adeln@tpims.org.

Scheme 1^a

^a Reagents and conditions: (a) 55% TFA/DCM, 1 h; (b) 20% piperidine/DMF, 10 min, twice; (c) benzyl isocyanide/cyclohexanone (1:1) in acetonitrile/MeOH (4:1); (d) HF/anisole, 1.5 h, 0 °C.

with 5% diisopropylethylamine (DIEA) in dichloromethane (DCM), L-Fmoc-Glu(^tBu)-OH (6eq) was coupled using the conventional reagents hydroxybenzotriazole (HOBt, 6 equiv) and diisopropylcarbodiimide (DIC, 6 equiv.) in anhydrous DMF for 2 h. Completion of the coupling was monitored by the ninhydrin test.¹⁴ Following removal of *t*-Butyl group with 55% TFA/DCM and washing with DCM (3×), the Fmoc group was deprotected with 20% piperidine in DMF (2 × 10 min). The resin was then washed with DMF (3×), ⁱPrOH (3×), and DCM (3×).


General Procedure for the Solid-Phase Ugi Reaction: Synthesis of Compounds 4 and 5. Resin 2 was put in a solution of ketone (2 equiv) in acetonitrile/methanol (4:1) for 1 h at 65 °C, and then isocyanide (2 equiv) was added. After the mixture was allowed to react at 65 °C for 24 h, the resin was washed with MeOH (3×), DMF (3×), and DCM (3×) and dried. The completeness of the reaction was verified by cleavage and analysis with LC-MS.

4. ¹H NMR (DMSO-*d*₆): δ 1.30–1.86 (m, 10H, H on cyclohexane ring); 2.12–2.29 (m, 4H, H on pyrrolidine ring); 4.24 (m, 2H, H on benzyl group); 4.56 (m, 1H, H on pyrrolidine ring); 7.08–7.18 (m, 5H, H on benzyl group); 7.49 (s, 1H, H on amide group); 7.98 (s, 1H, H on amide group); 9.00 (t, 1H, *J* = 5.8 Hz, H on amide group). ¹³C NMR (DMSO-*d*₆): δ 21.69 (C on piperidine ring), 22.12 (C on piperidine ring), 24.75 (C on pyrrolidine ring), 25.20 (C on piperidine ring), 29.64 (C on pyrrolidine ring), 31.00 (C on piperidine ring), 32.44 (C on piperidine ring), 42.18

(C on benzyl group), 58.24 (C on piperidine ring), 61.79 (C on pyrrolidine ring), 126.40 (C on benzyl group), 126.80 (2C, C on benzyl group), 128.03 (2C, C on benzyl group), 139.66 (C on benzyl group), 173.12 (C on amide group), 174.64 (C on amide group), 176.81 (C on amide group). ESI-MS: 343 (MH⁺).

5a. ¹H NMR (DMSO-*d*₆): δ 1.71–1.89 (m, 4H, H on piperidine ring), 2.15–2.34 (m, 3H, H on piperidine ring), 2.76–2.89 (m, 2H, H on piperidine ring), 3.02–3.23 (m, 4H, m, 4H, H on pyrrolidine ring), 4.28 (m, 2H, H on benzyl group), 4.52 (m, 1H, H on pyrrolidine ring), 7.19–7.30 (m, 5H, H on benzyl group), 7.53 (s, 1H, H on amide group), 8.06 (s, 1H, H on amide group), 9.18 (t, 1H, *J* = 5.7 Hz, H on amide group). ESI-MS: 345 (MH⁺).

Table 2. Synthesis of Substituted Pyrrolidinones




Entry	R ₁	Y	X	Obtained MW	Yield (%) ^a
5a		-NBoc-	-NH-	345 (MH ⁺)	80
5b		-CH ₂ -	-CH ₂ -	336 (MH ⁺)	82
5c		-CH ₂ -	-CH ₂ -	310 (MH ⁺)	78
5d		-CH ₂ -	-CH ₂ -	367 (MH ⁺)	70

Table 1. Screening of Reaction Conditions for the Solid-Phase Ugi Multi-Component Reaction

entry	reagents (equiv)				time (h)	temp (°C)	yield (%) ^a
	PS	Glu	BnNC	cyclohexanone			
4a	1	1.1	1.1	24	65	58	
4b	1	1.5	1.5	24	65	75	
4c	1	2	2	24	65	83	
4d	1	2	2	12	65	66	
4e	1	2	2	24	25	51	

^a Yields based on the weight of purified product and are relative to the initial loading of the resin. The purity of the purified compounds is higher than 95% for all the compounds. The purity was estimated on analytical traces at λ = 214 and 254 nm.

^a Yields based on the weight of purified product and are relative to the initial loading of the resin. The purity of the purified compounds is higher than 95% for all the compounds. The purity was estimated on analytical traces at λ = 214 and 254 nm.

Scheme 2^a

^a Reagents and conditions: (a) benzyl isocyanide, *N*-Boc-4-piperidinone, acetonitrile/methanol (4:1), 65 °C, 24 h; (b) 55% TFA/DCM; (c) acid, DIC, HOBT, DMF, rt, overnight or sulfonyl chloride/isocyanate/thioisocyanate, DIEA, DMF, rt, overnight; (d) HF cleavage, 0 °C, 1.5 h.

Table 3. Substituted Piperidine Products Obtained

Entry	R	Obtained MW	Yield (%) ^a
8 a		449 (MH ⁺)	76
8 b		463 (MH ⁺)	72
8 c		521 (MH ⁺)	68
8 d		499 (MH ⁺)	82
8 e		535 (MH ⁺)	85
8 f		430 (MH ⁺)	74
8 g		464 (MH ⁺)	79
8 h		432 (MH ⁺)	72
8 i		480 (MH ⁺)	80

^a Yields based on the weight of purified product and are relative to the initial loading of the resin. The purity of the purified compounds is higher than 95% for all the compounds. The purity was estimated on analytical traces at $\lambda = 214$ and 254 nm.

5b. ¹H NMR (DMSO-*d*₆): δ 1.11–1.86 (m, 20H, H on two piperidine rings), 2.08–2.28 (m, 4H, H on pyrrolidine ring), 3.48 (m, 1H, H on piperidine ring), 4.53 (m, 1H, H on pyrrolidine ring), 7.52 (s, 1H, H on amide group), 7.93 (s, 1H, H on amide group), 8.47 (m, 1H, H on amide group). ESI-MS: 336 (MH⁺).

5c. ¹H NMR (DMSO-*d*₆): δ 0.84 (t, 3H, J = 7.3 Hz, H on the *n*-butyl group), 1.23–1.86 (m, 14H, H on the *n*-butyl group and cyclohexane ring), 2.09–2.28 (m, 4H, H on pyrrolidine ring), 2.99 (q, 2H, J = 6.5 Hz, H on the *n*-butyl group), 4.53 (m, 1H, H on pyrrolidine ring), 7.50 (s, 1H, H on amide group), 7.96 (s, 1H, H on amide group), 8.48 (m, 1H, H on amide group). ESI-MS: 310 (MH⁺).

5d. ¹H NMR (DMSO-*d*₆): δ 1.28–1.86 (m, 10H, H on cyclohexane ring), 2.07–2.31 (m, 10H, H on 2-morpholinethyl group and pyrrolidine ring), 3.11 (m, 2H, H on 2-morpholinethyl group), 3.53 (t, 4H, J = 4.6 Hz, H on 2-morpholinethyl group), 4.51 (m, 1H, H on pyrrolidine ring), 7.44 (m, 1H, H on amide group), 7.92 (m, 1H, H on amide group), 8.47 (t, 1H, J = 5.5 Hz, H on amide group). ESI-MS: 367 (MH⁺).

General Procedure for the Synthesis of Compounds 8a–8c. Resin **5a** was shaken in 55% TFA/DCM for 30 min to remove the Boc group. Following neutralization with 5% DIEA/DCM, the resin was coupled with a carboxylic acid (6 equiv) using conventional reagents HOBT (6 equiv) and DIC (6 equiv) in anhydrous DMF overnight. The resin was then washed with DMF (3 \times) and DCM (3 \times), dried, and cleaved with HF for 1.5 h at 0 °C. All samples were purified by preparative HPLC and characterized by LC-MS and ¹H-NMR.

8a. ¹H NMR (DMSO-*d*₆): δ 1.75–2.32 (m, 8H, H on piperidine ring), 3.46 (m, 4H, H on pyrrolidine ring), 4.28 (m, 2H, H on benzyl group), 4.57 (m, 1H, H on pyrrolidine ring), 7.20–7.28 (m, 5H, H on benzyl group), 7.37–7.39 (m, 2H, H on benzoyl group), 7.42–7.45 (m, 3H, H on benzoyl group), 7.53 (m, 1H, H on amide group), 7.96 (m, 1H, H on amide group), 9.11 (m, 1H, H on amide group). ESI-MS: 449 (MH⁺).

8b. ¹H NMR (DMSO-*d*₆): δ 1.70–2.37 (m, 8H, H on piperidine ring), 3.40 (m, 4H, H on pyrrolidine ring), 3.67 (m, 2H, H on 2-phenylacetyl group), 4.26 (m, 2H, H on benzyl group), 4.48 (m, 1H, H on pyrrolidine ring), 7.19–7.23 (m, 6H, H on benzyl group and 2-phenylacetyl group), 7.26–7.32 (m, 4H, H on 2-phenylacetyl group), 7.52 (m, 1H, H on amide group), 7.95 (m, 1H, H on amide group), 9.12 (t, 1H, J = 5.7 Hz, H on amide group). ESI-MS: 463 (MH⁺).

8c. ¹H NMR (DMSO-*d*₆): δ 1.58–2.31 (m, 25H, H on piperidine ring and adamantyl group), 3.40 (m, 4H, H on pyrrolidine ring), 4.27 (m, 2H, H on benzyl group), 4.51 (m, 1H, H on pyrrolidine ring), 7.19–7.30 (m, 5H, H on benzyl group), 7.50 (m, 1H, H on amide group), 7.94 (s,

1H, H on amide group), 9.07–9.13 (m, 1H, H on amide group). ESI-MS: 521 (MH⁺).

General Procedure for the Synthesis of Compounds 8d–8i. Resin **5a** was shaken in 55% TFA/DCM for 30 min to remove the Boc group. Following neutralization with 5% DIEA/DCM, the resin was treated with DIEA (10 equiv) and corresponding reagents, such as sulfonyl chloride, isocyanate or thioisocyanate (10 equiv) in anhydrous DMF overnight. The resin was then washed with DMF (3×) and DCM (3×), dried and cleaved by HF for 1.5 h at 0 °C. All samples were purified by preparative HPLC and characterized.

8d. ¹H NMR (DMSO-*d*₆): δ 1.64–2.40 (m, 11H, H on piperidine ring and tosyl group), 3.41 (m, 4H, H on pyrrolidine ring), 4.15 (m, 2H, H on benzyl group), 4.49 (m, 1H, H on pyrrolidine ring), 7.13–7.26 (m, 5H, H on benzyl group), 7.44 (d, 2H, *J* = 8.3 Hz, H on tosyl group), 7.50 (s, 1H, H on amide group), 7.59 (d, 2H, *J* = 8.3 Hz, H on tosyl group), 7.94 (s, 1H, H on amide group), 8.98 (t, 1H, *J* = 5.7 Hz, H on amide group). ESI-MS: 499 (MH⁺).

8e. ¹H NMR (DMSO-*d*₆): δ 1.66–2.28 (m, 8H, H on piperidine ring), 3.49 (m, 4H, H on pyrrolidine ring), 4.09 (m, 2H, H on benzyl group), 4.49 (m, 1H, H on pyrrolidine ring), 7.07–7.20 (m, 5H, H on benzyl group), 7.50 (s, 1H, H on amide group), 7.69–7.76 (m, 3H, H on naphthalene-2-ylsulfonyl), 7.94 (s, 1H, H on amide group), 8.08 (d, 1H, *J* = 8.0 Hz, H on naphthalene-2-ylsulfonyl), 8.17 (d, 1H, *J* = 8.8 Hz, H on naphthalene-2-ylsulfonyl), 8.21 (d, 1H, *J* = 8.2 Hz, H on naphthalene-2-ylsulfonyl), 8.41 (s, 1H, H on naphthalene-2-ylsulfonyl), 8.95 (t, 1H, *J* = 5.6 Hz, H on amide group). ESI-MS: 535 (MH⁺).

8f. ¹H NMR (DMSO-*d*₆): δ 1.04 (d, 6H, *J* = 6.5, H on the isopropyl group), 1.58–2.37 (m, 8H, H on piperidine ring), 3.44 (m, 4H, H on pyrrolidine ring), 3.73 (m, 1H, H on the isopropyl group), 4.27 (m, 2H, H on benzyl group), 4.51 (m, 1H, H on pyrrolidine ring), 6.86 (s, 1H, H on urea), 7.19–7.30 (m, 5H, H on benzyl group), 7.52 (s, 1H, H on amide group), 7.96 (s, 1H, H on amide group), 9.09 (t, 1H, *J* = 5.7 Hz, H on amide group). ESI-MS: 430 (MH⁺).

8g. ¹H NMR (DMSO-*d*₆): δ 1.24–2.34 (m, 8H, H on piperidine ring), 3.58 (m, 4H, H on pyrrolidine ring), 4.29 (m, 2H, H on benzyl group), 4.54 (m, 1H, H on pyrrolidine ring), 7.20–7.30 (m, 7H, H on benzyl group and phenyl group), 7.44 (m, 2H, H on phenyl group), 7.53 (s, 1H, H on amide group), 7.96 (s, 1H, H on amide group), 8.47 (s, 1H, H on urea), 9.13 (t, 1H, *J* = 5.8 Hz, H on amide group). ESI-MS: 464 (MH⁺).

8h. ¹H NMR (DMSO-*d*₆): δ 1.08 (t, 3H, *J* = 7.2 Hz, H on ethyl group), 1.23–2.38 (m, 8H, H on piperidine ring), 3.41–3.48 (m, 6H, H on pyrrolidine ring and ethyl group), 4.28 (m, 2H, H on benzyl group), 4.50 (m, 1H, H on pyrrolidine ring), 6.87 (s, 1H, H on thiourea), 7.19–7.30 (m, 5H, H on benzyl group), 7.54 (s, 1H, H on amide group), 7.97 (s, 1H, H on amide group), 9.15 (t, 1H, *J* = 5.7 Hz, H on amide group). ESI-MS: 432 (MH⁺).

8i. ¹H NMR (DMSO-*d*₆): δ 1.23–2.38 (m, 8H, H on piperidine ring), 3.50–3.89 (m, 4H, H on pyrrolidine ring), 4.30 (m, 2H, H on benzyl group), 4.56 (m, 1H, H on pyrrolidine ring), 7.09 (m, 1H, H on benzyl group), 7.28 (m, 9H, H on benzyl group and phenyl group), 7.56 (s, 1H,

H on amide group), 8.00 (s, 1H, H on amide group), 9.19 (t, 1H, *J* = 5.7 Hz, H on amide group), 9.28 (s, 1H, H on thiourea). ESI-MS: 480 (MH⁺).

Acknowledgment. The authors would like to thank the State of Florida Funding, NIH (1R03DA025850-01A1, Nefzi), NIH (5P41GM081261-03, Houghten), and NIH (3P41GM079590-03S1, Houghten) for their financial support.

Supporting Information Available. ¹H NMR and LC-MS of all the compounds. This information is available free of charge via the Internet at <http://pubs.acs.org/>.

References and Notes

- (1) (a) Ziegert, R. E.; Toräng, J.; Knepper, K.; Bräse, S. *J. Comb. Chem.* **2005**, *7*, 147–169. (b) Kundu, B. *Curr. Opin. Drug Discovery Dev.* **2003**, *6*, 815–826. (c) Feliu, L.; Vera-Luque, P.; Albericio, F.; Alvarez, M. *J. Comb. Chem.* **2007**, *9*, 521–565. (d) Gil, C.; Bräse, S. *J. Comb. Chem.* **2009**, *11*, 175–197.
- (2) (a) *Multicomponent Reactions*; Zhu, J., Bienaymé, H., Eds.; Wiley-VCH: Weinheim, Germany, 2005 and references therein. (b) Simila, S. T. M.; Martin, S. F. *Tetrahedron Lett.* **2008**, *49*, 450. (c) El Kaim, L.; Grimaud, L. *Tetrahedron* **2009**, *65*, 2153. (d) Hulme, C.; Dietrich, J. *Mol. Diversity* **2009**, *13*, 195. (e) Dömling, A. *Chem. Rev.* **2006**, *106*, 17.
- (3) (a) Dömling, A. *Chem. Rev.* **2006**, *106*, 17–89. (b) Marcaccini, S.; Torroba, T. *Nat. Protoc.* **2007**, *2*, 632–639. (c) Dömling, A.; Ugi, I. *Angew. Chem., Int. Ed.* **2000**, *39*, 3168–3210. (d) Ugi, I.; Werner, B.; Dömling, A. *Molecules* **2003**, *8*, 53–56. (e) Main, M.; Snaith, J. S.; Meloni, M. M.; Jauregui, M.; Sykes, D.; Faulkner, S.; Kenwright, A. M. *Chem. Commun.* **2008**, 5212–5214.
- (4) (a) Pulici, M.; Quartieri, F.; Felder, E. R. *J. Comb. Chem.* **2005**, *7*, 463–473. (b) Hoel, A. M. L.; Nielson, J. *Tetrahedron Lett.* **1999**, *40*, 3941–3944. (c) Tempest, R. A.; Brown, S. D.; Armstrong, R. W. *Angew. Chem., Int. Ed. Engl.* **1996**, *35*, 640. (d) Lin, Q.; O'Neill, J. C.; Blackwell, H. E. *Org. Lett.* **2005**, *7*, 4455. (e) Stocker, A. M.; Keating, T. A.; Tempest, P. A.; Armstrong, R. W. *Tetrahedron Lett.* **1996**, *37*, 1149. (f) Golebiowski, A.; Jozwik, J.; Klopfenstein, S. R.; Colson, A.-O.; Grieb, A. L.; Russell, A. F.; Rastogi, V. L.; Diven, C. F.; Portlock, D. E.; Chen, J. J. *J. Comb. Chem.* **2002**, *4*, 584. (g) Golebiowski, A.; Jozwik, J.; Klopfenstein, S. R.; Colson, A.-O.; Grieb, A. L.; Russell, A. F.; Rastogi, V. L.; Diven, C. F.; Portlock, D. E.; Chen, J. J. *J. Comb. Chem.* **2002**, *4*, 584–590. (h) Suda, A.; Ohta, A.; Sudoh, M.; Tsukuda, T.; Shimma, N. *Heterocycles* **2001**, *55*, 1023. (i) Sutherland, D. P.; Stark, T. M.; Hughes, R.; Armstrong, R. W. *J. Org. Chem.* **1996**, *61*, 8350. (j) Stocker, A. M.; Keating, T. A.; Tempest, P. A.; Armstrong, R. W. *Tetrahedron Lett.* **1996**, *37*, 1149.
- (5) Hanessian, S.; Yun, H.; Hou, Y.; Tintelnot-Blomley, M. J. *Org. Chem.* **2005**, *70*, 6746–6756.
- (6) Iserloh, U.; Pan, J.; Stamford, A. W.; Kennedy, M. E.; Zhang, Q.; Zhang, L.; Parker, E. M.; McHugh, N. A.; Favreau, L.; Strickland, C.; Voit, J. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 418–422.
- (7) Washburn, D. G.; Hoang, T. H.; Frazee, J. S.; Johnson, L.; Hammond, M.; Manns, S.; Madauss, K. P.; Williams, S. P.; Duraiswami, C.; Tran, T. B.; Stewart, E. L.; Grygielko, E. T.; Glace, L. E.; Trizna, W.; Nagilla, R.; Bray, J. D.; Thompson, S. K. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 4664–4668.
- (8) Jiang, W.; Tucci, F. C.; Tran, J. A.; Fleck, B. A.; Wen, J.; Markison, S.; Marinkovic, D.; Chen, C. W.; Arellano, M.; Hoare, S. R.; Johns, M.; Foster, A. C.; Saunders, J.; Chen, C. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 5610–5613.
- (9) (a) Gong, Y.; Becker, M.; Choi-Sledeski, Y. M.; Davis, R. S.; Salvono, J. M.; Chu, V.; Brown, K. D.; Pauls, H. W. *Bioorg.*

- Med. Chem. Lett.* **2000**, *10*, 1033–1036. (b) Choi-Sledeski, Y. M.; McGarry, D. G.; Green, D. M.; Mason, H. J.; Becker, M. R.; Davis, R. S.; Ewing, W. R.; Dankulich, W. P.; manetta, V. E.; Morris, R. L.; Spada, A. P.; Cheney, D. L.; Brown, K. D.; Colussi, D. J.; Chu, V.; Heran, C. L.; Morgan, S. R.; Bentley, R. G.; Leadley, R. J.; Maigan, S.; Guilloteau, J. P.; Dunwiddie, C. T.; Pauls, H. W. *J. Med. Chem.* **1999**, *42*, 3572–3587.
- (10) Melamed, J. Y.; Egbertson, M. S.; Varga, S.; Vacca, J. P.; Moyer, G.; Gabryelski, L.; Felock, P. J.; Stillmock, K. A.; Witmer, M. V.; Schleif, W.; Hazuda, D. J.; Leonard, Y.; Jin, L.; Ellis, J. D.; young, S. D. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 5307–5310.
- (11) (a) Pelletier, S. M. C.; Ray, P. C.; Dixon, D. J. *Org. Lett.* **2009**, *11*, 4512–4515. (b) Donohoe, T. J.; Chiu, J. Y. K.; Thomas, R. E. *Org. Lett.* **2007**, *9*, 421–424. (c) Tellitu, I.; Serna, S.; Herrero, M. T.; Moreno, I.; Dominguez, E.; SanMartin, R. *J. Org. Chem.* **2007**, *72*, 1526–1529. (d) Medina, J. R.; Blackledge, C. W.; Erhard, K. F.; Axten, J. M.; Miller, W. H. *J. Org. Chem.* **2008**, *73*, 3946–3949. (e) Wardrop, D. J.; Burge, M. S. *J. Org. Chem.* **2005**, *70*, 10271–10284.
- (12) Gedey, S.; Van der Eycken, J.; Fulop, F. *Org. Lett.* **2002**, *4*, 1967–1969.
- (13) Houghten, R. A. *Proc. Natl. Acad. Sci. U.S.A.* **1985**, *82*, 5131.
- (14) Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. *Anal. Biochem.* **1970**, *34*, 595.

CC100054U